c-MYC—Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease
暂无分享,去创建一个
[1] J. Whitfield,et al. Tumor microenvironment: becoming sick of Myc , 2011, Cellular and Molecular Life Sciences.
[2] J. Sanders,et al. Postnatal liver growth and regeneration are independent of c-myc in a mouse model of conditional hepatic c-myc deletion , 2012, BMC Physiology.
[3] J. Horton,et al. Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.
[4] H. Jansen,et al. Oncogenes in retroviruses and cells: biochemistry and molecular genetics. , 1986, Advances in cancer research.
[5] S. Friedman. Molecular mechanisms of hepatic fibrosis and principles of therapy , 1997, Journal of Gastroenterology.
[6] X. Guan,et al. Prognostic significance of c‐myc and AIB1 amplification in hepatocellular carcinoma , 2002, Cancer.
[7] Alex Mas,et al. Overexpression of c‐myc in the liver prevents obesity and insulin resistance , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[8] F. Bosch,et al. Evidence from transgenic mice that myc regulates hepatic glycolysis , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[9] Shelly C. Lu,et al. Deregulated methionine adenosyltransferase α1, c‐Myc, and Maf proteins together promote cholangiocarcinoma growth in mice and humans‡ , 2016, Hepatology.
[10] Stuart H. Orkin,et al. A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.
[11] Shelly C. Lu,et al. Switch from Mnt‐Max to Myc‐Max induces p53 and cyclin D1 expression and apoptosis during cholestasis in mouse and human hepatocytes , 2009, Hepatology.
[12] M. Lindström,et al. Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts , 2003, Oncogene.
[13] S. Thorgeirsson,et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. , 2009, Cancer research.
[14] R. Braren,et al. c-myc in the hematopoietic lineage is crucial for its angiogenic function in the mouse embryo , 2008, Development.
[15] C. Dang,et al. Induction of ribosomal genes and hepatocyte hypertrophy by adenovirus-mediated expression of c-Myc in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[16] M. Pickering,et al. miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression , 2009, Oncogene.
[17] C. Robert Cloninger,et al. Genetics of Alcoholism and Related End-Organ Damage , 1988, Seminars in liver disease.
[18] L. Penn,et al. Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.
[19] S. Thorgeirsson,et al. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis. , 1993, Cancer research.
[20] N. Iizuka,et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus , 2006, Journal of Cancer Research and Clinical Oncology.
[21] John S Lazo,et al. Improved low molecular weight Myc-Max inhibitors , 2007, Molecular Cancer Therapeutics.
[22] S. Thorgeirsson,et al. E2F1 blocks and c-Myc accelerates hepatic ploidy in transgenic mouse models. , 2003, Biochemical and biophysical research communications.
[23] J. Radziuk,et al. Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis , 2001, Diabetes/metabolism research and reviews.
[24] Michael Q. Zhang,et al. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[25] N. Thompson,et al. Sequential protooncogene expression during rat liver regeneration. , 1986, Cancer research.
[26] B. Edgar,et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. , 2003, Genes & development.
[27] D. Felsher,et al. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[28] Chi V Dang,et al. MYC on the Path to Cancer , 2012, Cell.
[29] D. Felsher,et al. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[30] M E Greenberg,et al. Myc requires distinct E2F activities to induce S phase and apoptosis. , 2001, Molecular cell.
[31] P. Borro,et al. Alcohol and hepatocellular carcinoma: a review and a point of view. , 2014, World journal of gastroenterology.
[32] G. Evan,et al. Myc-Is this the oncogene from Hell? , 2002, Cancer cell.
[33] R. Eils,et al. Etiology‐dependent molecular mechanisms in human hepatocarcinogenesis , 2007, Hepatology.
[34] S. Thorgeirsson,et al. Transgenic Mouse Model for Synergistic Effects of Nuclear Oncogenes and Growth Factors in Tumorigenesis: Interaction of c-myc and Transforming Growth Factor α in Hepatic Oncogenesis , 1993 .
[35] D. Felsher,et al. Hepatotoxin-Induced Changes in the Adult Murine Liver Promote MYC-Induced Tumorigenesis , 2008, PloS one.
[36] G. Kay,et al. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. , 1995, Oncogene.
[37] Y. Fukuda,et al. Expression of oncogenes in human liver disease. , 2008, Liver.
[38] A. Grinberg,et al. Visualization of Myc/Max/Mad Family Dimers and the Competition for Dimerization in Living Cells , 2004, Molecular and Cellular Biology.
[39] E. Prochownik,et al. Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc–Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice , 2009, Cancer Chemotherapy and Pharmacology.
[40] K. Ko,et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. , 2011, Gastroenterology.
[41] T. Morgan,et al. Alcohol and hepatocellular carcinoma. , 2004, Gastroenterology.
[42] F. Tacke,et al. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. , 2013, Biochimica et biophysica acta.
[43] N. Lydon,et al. Electroporation of cultured adult rat hepatocytes with the c-myc gene potentiates DNA synthesis in response to epidermal growth factor. , 1988, Experimental cell research.
[44] J. Pawlotsky,et al. Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events , 2013, Oncogene.
[45] P. Borro,et al. Alcohol and gastrointestinal oncology. , 2010, World journal of gastrointestinal oncology.
[46] Francesco Donato,et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.
[47] S. Thorgeirsson,et al. Transgenic mouse models in carcinogenesis: interaction of c-myc with transforming growth factor alpha and hepatocyte growth factor in hepatocarcinogenesis. , 2003, British journal of clinical pharmacology.
[48] C. Trautwein,et al. Application of magnetic resonance imaging in transgenic and chemical mouse models of hepatocellular carcinoma , 2010, Molecular Cancer.
[49] D. W. Goodwin. Genetic influences in alcoholism. , 1987, Advances in internal medicine.
[50] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[51] P. Neiman,et al. Genomic instability during Myc-induced lymphomagenesis in the bursa of Fabricius , 2006, Oncogene.
[52] Kyoichi Inoue,et al. Hypomethylation of the c-myc oncogene in liver cirrhosis and chronic hepatitis , 1989, Gastroenterologia Japonica.
[53] N. Thompson,et al. Proto-oncogene expression and growth factors during liver regeneration. , 1986, Symposium on Fundamental Cancer Research.
[54] D. Calvisi,et al. Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer , 2015, Oncotarget.
[55] Vijay Kumar,et al. Hepatocellular carcinoma in a hepatitis B ‘x’ transgenic mouse model: A sequential pathological evaluation , 2003, Journal of gastroenterology and hepatology.
[56] E. Ziff,et al. The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max , 1995, Molecular and cellular biology.
[57] L. Hurley,et al. Targeting MYC Expression through G-Quadruplexes. , 2010, Genes & cancer.
[58] C. Croce,et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[59] A. Bradley,et al. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. , 1993, Genes & development.
[60] G. Evan,et al. Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max , 1992, Nature.
[61] Howard Y. Chang,et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. , 2006, Cancer research.
[62] Zhiping Weng,et al. Global mapping of c-Myc binding sites and target gene networks in human B cells , 2006, Proceedings of the National Academy of Sciences.
[63] David E. Muench,et al. c-Myc and Cancer Metabolism , 2012, Clinical Cancer Research.
[64] E. Prochownik,et al. MYC oncogenes and human neoplastic disease , 1999, Oncogene.
[65] J. Sanders,et al. Nucleolar localization of hepatic c-Myc: a potential mechanism for c-Myc regulation. , 2005, Biochimica et biophysica acta.
[66] R. Palmiter,et al. Oncogene-induced liver neoplasia in transgenic mice. , 1989, Oncogene.
[67] Christopher H. Contag,et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.
[68] C. Dang,et al. Conditional deletion of c-myc does not impair liver regeneration. , 2006, Cancer research.
[69] H. Hsu,et al. Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance. , 1993, Journal of the Formosan Medical Association = Taiwan yi zhi.
[70] S. Thorgeirsson,et al. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. , 2008, Gastroenterology.
[71] O. Perez,et al. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. , 2008, Cancer research.
[72] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[73] M. Buendia,et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice , 1997, Oncogene.
[74] Jennifer A. Smith,et al. The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3 , 2011, Molecular and Cellular Biology.
[75] S. Thorgeirsson,et al. Molecular analyses of liver tumors in c-myc transgenic mice and c-myc and TGF-alpha double transgenic mice. , 1996, Cancer Letters.
[76] Masaomi Kato,et al. microRNAs: small molecules with big roles –C. elegans to human cancer , 2008, Biology of the cell.
[77] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[78] P. Gallant,et al. Max-independent functions of Myc in Drosophila melanogaster , 2008, Nature Genetics.
[79] A. Sumberaz,et al. Human carcinogenesis and alcohol in hepato-gastroenterology. , 2012, European review for medical and pharmacological sciences.
[80] M. Strauss,et al. Lack of p53 accelerates hepatocarcinogenesis in transgenic mice constitutively overexpressing c‐myc in the liver , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[81] Bruno Amati,et al. Oncogenic activity of the c-Myc protein requires dimerization with Max , 1993, Cell.
[82] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[83] S. Schreiber,et al. Signaling Network Model of Chromatin , 2002, Cell.
[84] X. Wang,et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer , 2010, Proceedings of the National Academy of Sciences.
[85] C. Day,et al. Genetic predisposition to alcoholic liver disease. , 1992, Gut.
[86] P. Vogt,et al. Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[87] S. Ahn,et al. Development of a transgenic mouse model of hepatocellular carcinoma with a liver fibrosis background , 2016, BMC Gastroenterology.
[88] E. Prochownik. c-Myc: linking transformation and genomic instability. , 2008, Current molecular medicine.
[89] S. Cairo,et al. Myc target miRs and liver cancer: small molecules to get Myc sick. , 2012, Gastroenterology.
[90] R. Eisenman,et al. Myc and Max proteins possess distinct transcriptional activities , 1992, Nature.
[91] C. Dang,et al. Max: functional domains and interaction with c-Myc. , 1992, Genes & development.
[92] D. Felsher,et al. Inactivation of MYC reverses tumorigenesis , 2014, Journal of internal medicine.
[93] M. Avila,et al. New molecular interactions of c‐Myc in cholangiocarcinoma may open new therapeutic opportunities , 2016, Hepatology.
[94] R. Brůha,et al. Alcoholic liver disease. , 2012, World journal of hepatology.
[95] G. Wahl,et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.
[96] H. El‐Serag. Hepatocellular carcinoma and hepatitis C in the United States , 2002, Hepatology.
[97] C. Martínez-A,et al. c-Myc regulates cell size and ploidy but is not essential for postnatal proliferation in liver. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[98] Kathryn A. O’Donnell,et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.
[99] M. Muroni,et al. Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. , 2003, Carcinogenesis.
[100] P. Leder,et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[101] R. Eisenman,et al. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. , 1991, Science.
[102] J. Ward,et al. Role of Myc in hepatocellular proliferation and hepatocarcinogenesis. , 2014, Journal of hepatology.
[103] M. Lai,et al. Genome of avian myelocytomatosis virus MC29: analysis by heteroduplex mapping. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[104] R. Bataller,et al. Alcoholic liver disease: pathogenesis and new therapeutic targets. , 2011, Gastroenterology.
[105] M. Rattray,et al. A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. , 2006, Gastroenterology.
[106] J. Chow,et al. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells , 2007, Anti-cancer drugs.
[107] Vijay Kumar,et al. Specific inhibition of gene expression and transactivation functions of hepatitis B virus X protein and c‐myc by small interfering RNAs , 2004, FEBS letters.
[108] L. Roberts,et al. Myc, Max, and Mnt: molecular mechanisms of enhancement of cholangiocarcinogenesis by cholestasis. , 2011, Gastroenterology.
[109] M. Perricaudet,et al. Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the cmyc protooncogene at the transcriptional level. , 1991, Biochemical and biophysical research communications.
[110] F. Bosch,et al. Overexpression of c-myc in diabetic mice restores altered expression of the transcription factor genes that regulate liver metabolism. , 2002, The Biochemical journal.
[111] S. Lee,et al. Hepatitis B virus X protein enhances Myc stability by inhibiting SCFSkp2 ubiquitin E3 ligase-mediated Myc ubiquitination and contributes to oncogenesis , 2016, Oncogene.
[112] Dean W. Felsher,et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.
[113] S. Thorgeirsson,et al. MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism. , 2014, Cancer research.
[114] Chien-Ru Liu,et al. Targeting c-Myc as a novel approach for hepatocellular carcinoma. , 2010, World journal of hepatology.
[115] F. Heindryckx,et al. Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.
[116] Yu Wei,et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.
[117] J F Barrett,et al. Identification of CDK4 as a target of c-MYC. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[118] Y. Morishita,et al. Amplification of c-myc in Hepatocellular Carcinoma: Correlation with Clinicopathologic Features, Proliferative Activity and p53 Overexpression , 1999, Oncology.
[119] S. Thorgeirsson,et al. Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.
[120] F. Bosch,et al. Prevention of diabetic alterations in transgenic mice overexpressing Myc in the liver. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[121] Kathryn A. O’Donnell,et al. Hepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin. , 2016, JCI insight.
[122] T. Copetti,et al. Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review , 2011, Front. Pharmacol..
[123] F. Tacke,et al. Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. , 2015, Journal of hepatology.
[124] L. Zender,et al. A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer , 2016, Nature Medicine.
[125] J. Bishop,et al. DNA and RNA from Uninfected Vertebrate Cells Contain Nucleotide Sequences Related to the Putative Transforming Gene of Avian Myelocytomatosis Virus , 1979, Journal of virology.
[126] H. Hermeking,et al. Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.
[127] R. Cardiff,et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.
[128] J. Bartek,et al. E2F activity is essential for survival of Myc-overexpressing human cancer cells , 2002, Oncogene.
[129] J. Bishop. Retroviruses and cancer genes. , 1982, Advances in cancer research.
[130] Chi V. Dang,et al. c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.
[131] S. Thorgeirsson,et al. Coexpression of C‐myc and transforming growth factor alfa in the liver promotes early replicative senescence and diminishes regenerative capacity after partial hepatectomy in transgenic mice , 1997, Hepatology.
[132] Shuhan Sun,et al. Characterization of the genotype and integration patterns of hepatitis B virus in early‐ and late‐onset hepatocellular carcinoma , 2015, Hepatology.
[133] M. Vasseur-Cognet,et al. Glucose Regulation of Gene Transcription* , 2000, The Journal of Biological Chemistry.
[134] Vijay Kumar,et al. Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes. , 2006, Biochemical and biophysical research communications.